1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,430 | 4,560 | 03.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | 349 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 30.07. | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | 3 | pulse2.com | ||
| 28.07. | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | 470 | Business Wire | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| 24.07. | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | 271 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 07.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 279 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 482 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen | |
| 24.06. | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 327 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing... ► Artikel lesen | |
| 19.06. | MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 | 447 | Business Wire | Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025
MAA could be expected in H2 2026... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.06. | MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease | 390 | Business Wire | Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg
Independent dataset from EAP reinforces... ► Artikel lesen | |
| 02.06. | MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease | 437 | Business Wire | MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg
Xervyteghas... ► Artikel lesen | |
| 14.05. | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | 340 | Business Wire | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| 14.05. | MaaT Pharma to Hold Annual General Meeting on June 20, 2025 | 402 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 13.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 | 374 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 12.05. | MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 384 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | - | pharmaphorum | ||
| 28.04. | MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 343 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 319 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.04. | MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 363 | Business Wire | Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled... ► Artikel lesen | |
| 07.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co | 473 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 399 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEIDELBERG PHARMA | 3,030 | -2,57 % | Aktien KW 39 Mut fehlt, aber verpassen will man auch nichts. September abhaken und dann? News. Mutares. Nordex. SFC Energy. Artec. Circus. Heidelberg Pharma. Rheinmetall. Gerresheimer | Aktien:mBei rund 23.300 Punkten setzen spätestens Käufe ein, bei rund 23.800 Punkten werden die Anleger vorsichtig. So stellt sich der DAX im september dar - bisher. Und in den USA feiern die Märkte... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,800 | -0,46 % | Viking Therapeutics: Bald wieder im Rampenlicht? | Die Aktionäre von Viking Therapeutics mussten zuletzt einen herben Kursrückgang verkraften, während ein potenzieller Konkurrent für eine hohe Milliardenbewertung übernommen wurde. Dabei gilt Viking... ► Artikel lesen | |
| BAVARIAN NORDIC | 30,820 | -0,19 % | Bavarian Nordic A/S: Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian ... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 16,895 | -0,56 % | Figma, Beam, Intellia: Cathie Wood setzt auf riskante (Bio-)Tech-Aktien | Die bekannte US-Investorin Cathie Wood blieb ihrer Linie auch im August 2025 treu und griff wieder einmal beherzt bei spekulativen Tech- und Biotech-Werten zu. Mit ihrem wichtigsten Fonds, dem ARK Innovation... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,294 | +2,91 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
| CENTOGENE | 0,093 | -0,11 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 4,440 | +2,45 % | Atai Life Sciences files to sell 45.32M common shares by selling shareholders | ||
| BIOMERIEUX | 116,20 | -0,17 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| AC IMMUNE | 3,030 | -1,62 % | AC Immune SA: Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 3,813 | -6,40 % | Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries... ► Artikel lesen | |
| CYBIN | 5,250 | -0,94 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
| ADICET BIO | 0,719 | +1,34 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals | ||
| GENUS | 28,600 | +2,14 % | Genus - Total Voting Rights | ||
| ANAPTYSBIO | 26,800 | +1,52 % | AnaptysBio, Inc.: Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 | Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage... ► Artikel lesen |
MAAT PHARMA SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,180 (+4,38 %) liegt der Kurs bei 4,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.